Filed under: Investing
With ground breaking cystic fibrosis treatment data, Vertex (Nasdaq: VRTX) shares surged 40% in a single day last week. Kalydeco is already approved to treat are rare mutation occurring in 5% of cystic fibrosis suffers, but by combining it with experimental drug VX-809, Vertex is potentially bringing its treatment to nearly half of the CF population. Vertex's drugs special is that they treat the underlying cause of the disease and not just attempt to mitigate symptoms.
In this episode of Where The Money Is, Motley Fool health care analysts David Williamson and Michael Douglass give investors the background of Vertex, explain the sales potential of the CF treatment, discuss some concerns with the data, and whether it is to late to jump on the stock's bandwagon.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
The article 40% Pop: Is this Ground Breaking Biotech Still a Buy? originally appeared on Fool.com.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
Read | Permalink | Email this | Linking Blogs | Comments